Press Releases BioCorRx Inc.

Equities

BICX

US09073C2052

Delayed OTC Markets Other stock markets 09:45:16 2024-05-14 am EDT			5-day change	1st Jan Change
0.78 ^USD	0.00%		0.00%	0.00%

Apr. 03	BioCorRx Inc. Announces Board Resignations	CI
Apr. 01	BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia	Apr. 03	AQ
BioCorRx Reports Business Update for 2023	Apr. 02	AQ
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD	Feb. 28	AQ
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors	Feb. 08	AQ
BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President	Jan. 09	AQ
BioCorRx : Material Agreement - Form 8-K	Dec. 15	PU
BioCorRx Reports Business Update for the Third Quarter of 2023	Nov. 14	AQ
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder	23-08-15	AQ
BioCorRx Reports Business Update for the Second Quarter of 2023	23-08-14	AQ
BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder	23-07-18	AQ
BioCorRx Provides Business Update for the First Quarter of 2023	23-05-16	AQ
BIOCORRX INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	23-04-11	AQ
BIOCORRX INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	23-04-05	AQ
BioCorRx Provides Business Update for 2022	23-04-03	AQ
BIOCORRX INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-31	AQ
BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting	23-03-07	AQ
BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data	23-02-23	AQ
BioCorRx to Present at Sequire Biotechnology Conference on February 2nd	23-01-30	AQ
BioCorRx to Present at Sequire Biotechnology Conference on February 2nd	23-01-27	AQ
BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of Directors	23-01-24	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases BioCorRx Inc.

Equities

BICX

US09073C2052

Press Releases

Filters